Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK
In the middle of 2023, Richard Batycky told a couple of his fellow executives at Nocion Therapeutics to consider looking for roles elsewhere. He wasn’t sure the biotech would weather a difficult funding landscape.
Then, as the CEO was preparing for a vacation, a term sheet from an investor came through. Signs of a brighter day were ahead and Batycky would spend the next several months pulling together a $62 million Series B to fund Nocion’s inhaled chronic cough candidate NTX-1175, which will now be known under the name taplucanium, he told Endpoints News in an exclusive interview.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.